Tislelizumab is in clinical development to treat patients with localised oesophageal squamous cell carcinoma (ESCC). ESCC begins in the food pipe (oesophagus) and may spread to other parts of the body. Localised cancer is when it is still located only in the tissue or organ where it started, and has not spread to nearby lymph nodes or to other parts of the body. Symptoms include difficulty swallowing, persistent indigestion or heartburn, weight loss, pain in the throat, and chronic cough. In the UK it is more common in older people (≥75 years old) and males. There is a need for new treatment options, including immunotherapies, as ESCC progresses rapidly and has high mortality.
Tislelizumab in combination with Paclitaxel, Cisplatin, and Radiotherapy for Oesophageal cancer
Tislelizumab is in clinical development to treat patients with localised oesophageal squamous cell carcinoma (ESCC). ESCC begins in the food pipe (oesophagus) and may spread to other parts of the body. Localised cancer is when it is still located only in the tissue or organ where it started, and has not spread to nearby lymph nodes or to other parts of the body.
Interventions:
Cisplatin (Platinol)
, Paclitaxel (Taxol; paclitaxel albumin)
, Tislelizumab (BGB-A317; BGBA-317)
Indications:
Squamous cell carcinoma (SCC)
Therapeutic Areas:
Head and Neck Cancer
Year:
2022